Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CO-LAV vs ANDROID 10
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
CO-LAV is a combination of codeine and acetylsalicylic acid (aspirin). Codeine is a prodrug that is metabolized to morphine, which acts as an agonist at mu-opioid receptors, producing analgesia. Aspirin irreversibly inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis and providing analgesic, antipyretic, and anti-inflammatory effects.
Androgen receptor agonist; testicular androgen responsible for development and maintenance of male sex characteristics and anabolic effects; increases protein synthesis and muscle mass.
mild to moderate pain,fever,inflammation
Male hypogonadism (primary and hypogonadotropic),Delayed puberty in males,Off-label: Androgen replacement in transgender men (masculinizing hormone therapy)
Adults: 1 tablet (trimethoprim 80 mg/sulfamethoxazole 400 mg) orally twice daily for 5-7 days; for Pneumocystis jirovecii pneumonia, 2 tablets (160 mg/800 mg) orally every 6 hours for 21 days.
Testosterone undecanoate 750 mg (3 m L) intramuscular injection every 10 weeks, or testosterone cypionate 50-400 mg intramuscular injection every 2-4 weeks. For gel formulations: 50-100 mg transdermally once daily.
Unknown
8 hours; clinical context: steady-state achieved in 2-3 days, dosing interval 8-12 hours.
Codeine is metabolized via CYP2D6 to morphine (active), and via CYP3A4 to norcodeine, with further glucuronidation. Aspirin is rapidly hydrolyzed to salicylate by esterases in the gastrointestinal tract and liver; salicylate is primarily metabolized by conjugation with glycine (salicyluric acid) and glucuronic acid, with minor oxidation.
Hepatic metabolism via CYP3A4; undergoes extensive first-pass metabolism; metabolites primarily excreted renally.
CO-LAV is not a recognized drug. Please check the drug name.
Renal: 90% as glucuronide and sulfate conjugates, 6% as unchanged drug; fecal: 4%.
Unknown
97-99% bound primarily to sex hormone-binding globulin (SHBG) and albumin.
Unknown
0.5-1.0 L/kg; indicates extensive distribution into tissues and organs.
Unknown
Oral: low (variable, ~5-20% due to first-pass metabolism); intramuscular: 100%.
GFR 15-30 m L/min: administer 50% of standard dose every 12 hours; GFR <15 m L/min: contraindicated (except during hemodialysis, where 50% dose post-dialysis may be used).
No specific dose adjustment required for renal impairment; monitor serum testosterone levels and clinical response. For severe renal impairment (GFR <30 m L/min), consider increased monitoring due to potential fluid retention.
Child-Pugh Class A/B: no adjustment necessary; Child-Pugh Class C: contraindicated due to risk of severe hepatotoxicity.
Contraindicated in patients with severe hepatic dysfunction (Child-Pugh class C). For mild to moderate impairment (Child-Pugh class A or B), use with caution and consider dose reduction; monitor liver function tests regularly.
Children >2 months: 8 mg/kg/day (based on trimethoprim) in two divided doses for UTI; for PCP prophylaxis: 150 mg/m²/day in two divided doses on 3 consecutive days per week.
Not recommended for use in children; safety and efficacy not established. For delayed puberty in adolescent males: testosterone enanthate 50-200 mg intramuscularly every 2-4 weeks, titrated to response, with monitoring of bone age.
Increased risk of severe adverse reactions (e.g., hyperkalemia, renal impairment); monitor renal function and potassium levels; initiate at lower doses (e.g., half the standard dose) and titrate cautiously.
Start at low end of dosing range (e.g., testosterone cypionate 50 mg intramuscularly every 4 weeks or gel 25 mg daily) due to potential increased sensitivity and risk of prostatic hypertrophy or cardiovascular events. Monitor serum testosterone, hematocrit, and prostate-specific antigen (PSA).
Codeine is contraindicated in children younger than 12 years and in children younger than 18 years following tonsillectomy and/or adenoidectomy due to risk of respiratory depression and death associated with ultra-rapid metabolism of codeine to morphine. Aspirin is associated with Reye's syndrome in children and adolescents with viral illnesses.
None
Respiratory depression, risk of opioid addiction, abuse, and misuse; life-threatening respiratory depression in children with CYP2D6 ultra-rapid metabolizers; Reye's syndrome in children and adolescents with viral illnesses; increased risk of bleeding; gastrointestinal perforation and bleeding; renal impairment; hypersensitivity reactions including anaphylaxis and aspirin-sensitive asthma; drug interactions with CYP2D6 and CYP3A4 inhibitors/inducers; use in pregnancy and lactation.
Risk of hepatotoxicity; use with caution in patients with liver disease. Monitor liver function, lipid profile, and prostate-specific antigen (PSA). May cause fluid retention, gynecomastia, priapism, and sleep apnea. Not for use in women who are pregnant or breastfeeding. May accelerate growth of prostate cancer and benign prostatic hyperplasia. Androgenic effects may cause virilization in women.
Hypersensitivity to codeine, aspirin, or NSAIDs; children younger than 12 years; children younger than 18 years following tonsillectomy and/or adenoidectomy; significant respiratory depression; acute or severe bronchial asthma; paralytic ileus; bleeding disorders; concomitant use with MAOIs or within 14 days; third trimester of pregnancy; nursing mothers (due to aspirin); viral illness with fever in children and adolescents (risk of Reye's syndrome); concomitant use with anticoagulants (e.g., warfarin) due to bleeding risk.
Men with carcinoma of the prostate or breast; history of hypersensitivity to testosterone or any component; women who are pregnant or may become pregnant (risk of fetal harm); patients with severe hepatic or cardiac disease.
Grapefruit juice may increase colchicine levels due to CYP3A4 inhibition; avoid concurrent consumption. High-fat meals may reduce colchicine absorption? No data for colchicine specifically; take with or without food. Alcohol may worsen gout symptoms and increase risk of pancreatitis; avoid. Lactulose effect is not dependent on food; can be taken with or without meals.
No known food interactions. However, methyltestosterone can increase appetite and cause weight gain; a balanced diet is recommended.
First trimester: Not associated with major congenital malformations based on limited human data. Second and third trimesters: No specific fetal risks reported; however, placental transfer is minimal.
Android 10 is a combination of methyltestosterone and ethinyl estradiol. Methyltestosterone is an androgen; exposure during pregnancy, particularly during the first trimester, can cause virilization of the female fetus. Ethinyl estradiol is contraindicated in pregnancy due to risk of fetal harm. Use is contraindicated in all trimesters.
Considered compatible with breastfeeding. M/P ratio unknown; limited excretion into breast milk expected due to high protein binding and low oral bioavailability.
Methyltestosterone and ethinyl estradiol are excreted in breast milk. Methyltestosterone may cause virilization in female infants. Ethinyl estradiol may reduce milk production and quality. M/P ratio not available. Breastfeeding is contraindicated.
No dose adjustment required for pregnancy. Pharmacokinetics are not significantly altered in pregnancy; standard dosing recommended.
Contraindicated in pregnancy; no dosing adjustments apply. If inadvertent use occurs, discontinue immediately.
CO-LAV (colchicine/lactulose) is a fixed-dose combination used for gout flare prophylaxis but poses risks in renal impairment; colchicine dose must be reduced in CKD stage 4-5 due to narrow therapeutic index. Lactulose may cause bloating and flatulence; monitor for diarrhea-related electrolyte disturbances. Avoid concurrent use with strong CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole) and P-glycoprotein inhibitors (e.g., cyclosporine) to prevent colchicine toxicity. In liver impairment, colchicine accumulation can occur; use with caution. Geriatric patients are more susceptible to colchicine neurotoxicity and myopathy.
Android 10 is a brand name for methyltestosterone, an androgen and anabolic steroid. Use is restricted to replacement therapy in males with hypogonadism or delayed puberty due to androgen deficiency. Monitor liver function due to risk of peliosis hepatis and hepatocellular carcinoma. Contraindicated in males with breast or prostate cancer. Can cause erythrocytosis; monitor hematocrit. Discontinue if signs of virilization in women or priapism in men. Use caution in elderly due to increased risk of prostatic hypertrophy.
Take this medication exactly as prescribed; do not exceed the recommended dose of colchicine.,If you have kidney or liver disease, inform your doctor; dose adjustments may be needed.,Report any signs of colchicine toxicity: muscle pain, weakness, numbness, tingling, or unusual bruising/bleeding.,Lactulose may cause gas, bloating, or stomach cramps; these usually improve over time.,Stay well hydrated to prevent diarrhea-related dehydration.,Do not take any other medications, including over-the-counter, without consulting your doctor.,If you are pregnant, planning to become pregnant, or breastfeeding, discuss risks with your healthcare provider.,Store at room temperature away from moisture and heat.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Report signs of liver problems: yellowing of skin or eyes, dark urine, light-colored stools, abdominal pain.,Notify your doctor if you experience swelling of ankles or feet, trouble breathing, or persistent erections lasting more than 4 hours.,May cause aggressive behavior, mood swings, or depression; contact your doctor if these occur.,Do not take if you are pregnant or breastfeeding.,Keep all appointments for blood tests and liver function monitoring.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CO-LAV vs ANDROID 10, answered by our medical review team.
CO-LAV is a Laxative/Bowel Evacuant that works by CO-LAV is a combination of codeine and acetylsalicylic acid (aspirin). Codeine is a prodrug that is metabolized to morphine, which acts as an agonist at mu-opioid receptors, producing analgesia. Aspirin irreversibly inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis and providing analgesic, antipyretic, and anti-inflammatory effects.. ANDROID 10 is a Androgen that works by Androgen receptor agonist; testicular androgen responsible for development and maintenance of male sex characteristics and anabolic effects; increases protein synthesis and muscle mass.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CO-LAV and ANDROID 10 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CO-LAV is: Adults: 1 tablet (trimethoprim 80 mg/sulfamethoxazole 400 mg) orally twice daily for 5-7 days; for Pneumocystis jirovecii pneumonia, 2 tablets (160 mg/800 mg) orally every 6 hours for 21 days.. The standard adult dose of ANDROID 10 is: Testosterone undecanoate 750 mg (3 m L) intramuscular injection every 10 weeks, or testosterone cypionate 50-400 mg intramuscular injection every 2-4 weeks. For gel formulations: 50-100 mg transdermally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CO-LAV and ANDROID 10 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CO-LAV is classified as Category C. First trimester: Not associated with major congenital malformations based on limited human data. Second and third trimesters: No specific fetal risks reported; however, placental t. ANDROID 10 is classified as Category C. Android 10 is a combination of methyltestosterone and ethinyl estradiol. Methyltestosterone is an androgen; exposure during pregnancy, particularly during the first trimester, can . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.